| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Laurent Peyrin-Biroulet | Q30248039 |
| Fernando Magro | Q37840060 | ||
| Ailsa Hart | Q92024668 | ||
| P2093 | author name string | Alessandro Armuzzi | |
| Pieter Hindryckx | |||
| Filip Baert | |||
| Clinical Trial Committee Clincom of the European Crohn’s and Colitis Organisation (ECCO) | |||
| P2860 | cites work | Infliximab for induction and maintenance therapy for ulcerative colitis | Q28285876 |
| A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). | Q28362796 | ||
| Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance | Q29615569 | ||
| Cyclosporine in severe ulcerative colitis refractory to steroid therapy | Q34060783 | ||
| Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial | Q34156631 | ||
| Vedolizumab as induction and maintenance therapy for ulcerative colitis | Q34365566 | ||
| Microscopic activity in ulcerative colitis: what does it mean? | Q34393414 | ||
| A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research | Q35169255 | ||
| Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative | Q35286226 | ||
| Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. | Q35595821 | ||
| A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis | Q35768942 | ||
| Randomised controlled trial of azathioprine withdrawal in ulcerative colitis | Q35822294 | ||
| Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study | Q36328183 | ||
| A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis | Q36720357 | ||
| A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis | Q36720362 | ||
| Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease | Q37937180 | ||
| Ulcerative colitis as a progressive disease: the forgotten evidence | Q37967664 | ||
| Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations | Q38049779 | ||
| Deep remission in inflammatory bowel disease: looking beyond symptoms | Q38077111 | ||
| The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis | Q38092984 | ||
| Histologic remission: the ultimate therapeutic goal in ulcerative colitis? | Q38126285 | ||
| Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease | Q38188738 | ||
| Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity | Q38224249 | ||
| Converging goals of treatment of inflammatory bowel disease from clinical trials and practice | Q38240237 | ||
| An experiment to determine the active therapeutic moiety of sulphasalazine | Q39458926 | ||
| Ulcerative colitis: definition, historical background, aetiology, diagnosis, naturel history and local complications | Q40348424 | ||
| Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions | Q41067146 | ||
| An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis | Q43250765 | ||
| A double blind controlled trial of prednisolone-21-phosphate suppositories in the treatment of idiopathic proctitis | Q43250874 | ||
| Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis | Q43274153 | ||
| Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis | Q43582796 | ||
| Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy | Q43817874 | ||
| Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. | Q44755672 | ||
| Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease | Q45181649 | ||
| Deep remission in Crohn's disease: is it the end of the placebo effect? | Q45927341 | ||
| Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis | Q46184125 | ||
| Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis | Q46286038 | ||
| Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis | Q46990369 | ||
| Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial | Q49167560 | ||
| Comparing histological activity indexes in UC. | Q51051300 | ||
| Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. | Q53088825 | ||
| Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. | Q53122367 | ||
| Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. | Q54007642 | ||
| Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. | Q55266577 | ||
| Cortisone and corticotrophin in ulcerative colitis. | Q55480299 | ||
| Cortisone in ulcerative colitis; final report on a therapeutic trial. | Q55499879 | ||
| Infliximab, azathioprine, or combination therapy for Crohn's disease | Q56988763 | ||
| Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease | Q57265459 | ||
| Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial man | Q57265461 | ||
| Drug-induced Immunological Tolerance | Q59059733 | ||
| Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial | Q59120396 | ||
| P433 | issue | 7 | |
| P921 | main subject | ulcerative colitis | Q1477 |
| P304 | page(s) | 580-588 | |
| P577 | publication date | 2015-04-25 | |
| P1433 | published in | Journal of Crohn's and Colitis | Q15817379 |
| P1476 | title | Clinical trials in ulcerative colitis: a historical perspective | |
| P478 | volume | 9 |
| Q55284143 | Andrographolide presents therapeutic effect on ulcerative colitis through the inhibition of IL-23/IL-17 axis. |
| Q49835637 | Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany |
| Q39098635 | Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. |
| Q98894296 | Development of a Software for Treat-To-Target Strategy Implementation and Increasing Quality of Life in Patients with Inflammatory Bowel Disease |
| Q38977432 | Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis |
| Q40657731 | Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease. |
| Q38943959 | Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases |
| Q40408942 | Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing |
| Q92414863 | The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis |
| Q48059378 | The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. |
| Q50881664 | Treat to Target in Inflammatory Bowel Disease. |
Search more.